40 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Quality of Life in Neurological Disorders Cognitive Function Version 2 (Neuro-QoL CF v2) T-scores at 6 WeeksPrimary· Baseline and 6 weeks
Neuro-QoL CF v2 measures self-reported levels of cognitive functioning. Raw scores are converted to standardized T-scores (mean of 50 with a standard deviation of 10). Increase in T-scores from baseline indicates improvement in everyday cognitive functioning.
Baseline
Group
Value
95% CI
Mental Imagery
49.9
± 7.2
Psychoeducation
49.1
± 8.4
6 weeks
Group
Value
95% CI
Mental Imagery
50
± 7.2
Psychoeducation
45.9
± 5.1
Change in Neuro-QoL CF v2 T-scores at 18 WeeksPrimary· 18 weeks
Neuro-QoL CF v2 measures self-reported levels of cognitive functioning. Raw scores are converted to standardized T-scores (mean of 50 with a standard deviation of 10). Increase in T-scores from baseline indicates improvement in everyday cognitive functioning.
Baseline
Group
Value
95% CI
Mental Imagery
49.9
± 7.2
Psychoeducation
49.1
± 8.4
18 weeks
Group
Value
95% CI
Mental Imagery
49.4
± 7.4
Psychoeducation
46.9
± 6.1
Change in Composite Executive Function T-scores at 6 WeeksSecondary· 6 weeks
T-scores (mean of 50 with a standard deviation of 10) of executive function tests (i.e., Stroop, F-A-S letter fluency, and Trail Making B tests) were averaged to obtain a composite executive function score for each subject. Higher scores indicate better executive function.
Baseline
Group
Value
95% CI
Mental Imagery
53.1
± 7.9
Psychoeducation
48.7
± 7.4
6 weeks
Group
Value
95% CI
Mental Imagery
54.7
± 8.2
Psychoeducation
51
± 9.5
Change in Composite Executive Function T-scores at 18 WeeksSecondary· 18 weeks
T-scores (mean of 50 with a standard deviation of 10) of executive function tests (i.e., Stroop, F-A-S letter fluency, and Trail Making B tests) were averaged to obtain a composite executive function score for each subject. Higher scores indicate better executive function.
Baseline
Group
Value
95% CI
Mental Imagery
53.1
± 7.9
Psychoeducation
48.7
± 7.4
18 weeks
Group
Value
95% CI
Mental Imagery
55.1
± 9.6
Psychoeducation
49.5
± 7.8
Sponsor's own description
The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and magnetic resonance imaging (MRI).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other Yale University trials
Trials by the same sponsor.
NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking
· Phase 2
· not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing
· NA
· not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S
· NA
· not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa
· Phase 1, PHASE2
· not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495997.